Substance / Medication

Methdilazine

Overview

Active Ingredient
methdilazine
RxNorm CUI
29648

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

14 trials linked to this intervention

14
Total Trials
3
Recruiting
4
With Results

Research Evidence

Published studies and systematic reviews

Sort:
The efficacy of oral acyclovir during early course of pityriasis rosea: a systematic review and meta-analysis.
Chang Hua-Ching, Sung Chih-Wei, Lin Ming-Hsiu · J Dermatolog Treat · 2019
PMID: 30109959Meta-Analysis
Interventions for pityriasis rosea.
Chuh A A T, Dofitas B L, Comisel G G et al. · Cochrane Database Syst Rev · 2007
PMID: 17443568Meta-Analysis
Is human herpesvirus 7 the causative agent of pityriasis rosea?--A critical review.
Chuh Antonio A T, Chan Henry H L, Zawar Vijay · Int J Dermatol · 2004
PMID: 15569005Meta-Analysis
Efficacy of clarithromycin in pityriasis rosea.
Ahmed Najia, Iftikhar Nadia, Bashir Uzma et al. · J Coll Physicians Surg Pak · 2014
PMID: 25404436RCT
Oral erythromycin is ineffective in the treatment of pityriasis rosea.
Rasi Abbas, Tajziehchi Leila, Savabi-Nasab Said · J Drugs Dermatol · 2008
PMID: 18246696RCT
Antibacterial property of the antipsychotic agent prochlorperazine, and its synergism with methdilazine.
Rani Basu Laxmi, Mazumdar Kaushiki, Dutta Noton Kumar et al. · Microbiol Res · 2005
PMID: 15782943Other
Activity of the phenothiazine methdilazine alone or in combination with isoniazid or streptomycin against Mycobacterium tuberculosis in mice.
Dutta Noton K, Mazumdar Kaushiki, DasGupta Asish et al. · J Med Microbiol · 2009
PMID: 19696152Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Methdilazine (substance)
SNOMED CT
18462008
UMLS CUI
C0066101
RxNorm CUI
29648

Clinical Data

This intervention maps to 12 entities in the Healos knowledge graph.

7
Conditions
2
Biomarkers
2
Specialists
0
Symptoms
14
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.